Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LATS1 | O95835 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | KIF11 | P52732 | 3/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.35 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.34 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.34 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.34 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | SSTR4 | P31391 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12341054 | 0.91 | LATS1 (0.40) | LATS1ALDH1A1SLC22A12NPC1POLB | |
| SCHEMBL16167559 | 0.87 | KIF11 (0.34) | LATS1ALDH1A1SLC22A12NPC1POLB | |
| SCHEMBL20772453 | 0.86 | KIF11 (0.41) | LATS1ALDH1A1SLC22A12NPC1POLB | |
| SCHEMBL1705592 | 0.86 | KIF11 (0.39) | LATS1ALDH1A1KIF11GAAALOX5 | |
| SCHEMBL18235334 | 0.78 | KIF11 (0.34) | KIF11ALOX5PTGS1PTGS2 | |
| SCHEMBL16472122 | 0.76 | LOXL2 (0.38) | LATS1SLC22A12KIF11ALOX5PTGS1 | |
| SCHEMBL7808033 | 0.76 | LOXL2 (0.38) | LATS1SLC22A12KIF11ALOX5PTGS1 | |
| SCHEMBL1310290 | 0.76 | CYP17A1 (0.44) | LATS1ALDH1A1SLC22A12KIF11L3MBTL1 | |
| SCHEMBL803091 | 0.76 | LOXL2 (0.42) | LATS1SLC22A12KIF11ALOX5PTGS1 | |
| SCHEMBL18235336 | 0.76 | KIF11 (0.35) | ALDH1A1KIF11ALOX5PTGS1PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240226113-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | KUMQUAT BIOSCIENCES INC. | 2024-07-11 | — | — | US | disclosed |
| US-20240226113-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | KUMQUAT BIOSCIENCES INC. | 2024-07-11 | — | — | US | disclosed |
| US-RE49594-E1 | Apelin receptor (APJ) agonists and uses thereof | RESEARCH TRIANGLE INSTITUTE (US) | 2023-08-01 | — | — | US | disclosed |
| US-RE49594-E1 | Apelin receptor (APJ) agonists and uses thereof | RESEARCH TRIANGLE INSTITUTE (US) | 2023-08-01 | — | — | US | disclosed |
| US-11535630-B2 | Apelin receptor (APJ) agonists and uses thereof | RESEARCH TRIANGLE INSTITUTE (US) | 2022-12-27 | — | — | US | disclosed |
| US-20210094919-A1 | KRAS MUTANT PROTEIN INHIBITORS | JACOBIO PHARMACEUTICALS CO., LTD. | 2021-04-01 | — | — | US | disclosed |
| US-20210070767-A1 | APELIN RECEPTOR (APJ) AGONISTS AND USES THEREOF | RESEARCH TRIANGLE INSTITUTE | 2021-03-11 | — | — | US | disclosed |
| WO-2021043322-A1 | AZEPINO PYRIMIDINE DERIVATIVES AND MEDICAL USE THEREOF | 正大天晴药业集团南京顺欣制药有限公司 | 2021-03-11 | — | — | WO | disclosed |
| US-20210040089-A1 | KRAS MUTANT PROTEIN INHIBITORS | JACOBIO PHARMACEUTICALS CO., LTD. | 2021-02-11 | — | — | US | disclosed |
| US-20200347071-A1 | AMINOPYRROLOTRIAZINES AS KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2020-11-05 | — | — | US | disclosed |
| US-20090292014-A1 | BENZOFURAN DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS | ZHANG CHENGZHI | 2009-11-26 | — | — | US | disclosed |
| US-20090143412-A1 | FUROPYRIDINE AND FUROPYRIMIDINE DERIVATIVES FOR THE TREATMENT OF HYPER-PROLIFERATIVE DISORDERS | BAYER HEALTHCARE LLC (US) | 2009-06-04 | — | — | US | disclosed |
| US-20090143412-A1 | FUROPYRIDINE AND FUROPYRIMIDINE DERIVATIVES FOR THE TREATMENT OF HYPER-PROLIFERATIVE DISORDERS | BAYER HEALTHCARE LLC (US) | 2009-06-04 | — | — | US | disclosed |
| US-7498341-B2 | antidiabetic agents; type 2 diabetes | SANOFI AVENTIS DEUTSCHLAND GMBH (DE) | 2009-03-03 | — | — | US | disclosed |
| US-20090023783-A1 | BENZOFURAN DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS | ZHANG CHENGZHI | 2009-01-22 | — | — | US | disclosed |
| US-20080312435-A1 | Imine Compound | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2008-12-18 | — | — | US | disclosed |
| US-7429584-B2 | Furo[2.3-b]pyridine derivatives for the treatment of hyper-proliferative disorders | BAYER PHARMACEUTICALS CORPORATION (US) | 2008-09-30 | — | — | US | disclosed |
| US-7429584-B2 | Furo[2.3-b]pyridine derivatives for the treatment of hyper-proliferative disorders | BAYER PHARMACEUTICALS CORPORATION (US) | 2008-09-30 | — | — | US | disclosed |
| US-7420066-B2 | Benzofuran derivatives useful for treating hyper-proliferative disorders | BAYER PHARMACEUTICALS CORPORATION (US) | 2008-09-02 | — | — | US | disclosed |
| US-20080004287-A1 | Substituted Piperidines that Increase P53 Activity and the Uses Thereof | SCHERING CORPORATION | 2008-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080312435-A1 | Imine Compound | CNR1, CNR2, HRH4 | LATS1 3790/4885ALDH1A1 2674/4885SLC22A12 3821/4885 |
| US-20090292014-A1 | BENZOFURAN DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS | PCNA, MKI67, CDK4 | LATS1 831/4885ALDH1A1 609/4885SLC22A12 3241/4885 |
| US-20090143412-A1 | FUROPYRIDINE AND FUROPYRIMIDINE DERIVATIVES FOR THE TREATMENT OF HYPER-PROLIFERATIVE DISORDERS | NCOR1, NR3C1, NR3C2 | LATS1 1954/4885ALDH1A1 668/4885SLC22A12 1286/4885 |
| US-20080004287-A1 | Substituted Piperidines that Increase P53 Activity and the Uses Thereof | TP53, MDM2, TP53BP1 | LATS1 2449/4885ALDH1A1 1827/4885SLC22A12 3915/4885 |
| US-20200347071-A1 | AMINOPYRROLOTRIAZINES AS KINASE INHIBITORS | RIPK1, RIPK2, RIPK4 | LATS1 522/4885ALDH1A1 4108/4885SLC22A12 4396/4885 |
| US-11535630-B2 | Apelin receptor (APJ) agonists and uses thereof | APLNR, AP1G1, APMAP | LATS1 4280/4885ALDH1A1 3849/4885SLC22A12 3327/4885 |
| US-20240226113-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | TP53, HRAS, KRAS | LATS1 501/4885ALDH1A1 2917/4885SLC22A12 3945/4885 |
| US-20210070767-A1 | APELIN RECEPTOR (APJ) AGONISTS AND USES THEREOF | APLNR, AP1G1, APMAP | LATS1 4280/4885ALDH1A1 3849/4885SLC22A12 3327/4885 |
| US-20090023783-A1 | BENZOFURAN DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS | PCNA, MKI67, CDK4 | LATS1 831/4885ALDH1A1 609/4885SLC22A12 3241/4885 |
| US-20210040089-A1 | KRAS MUTANT PROTEIN INHIBITORS | KRAS, NRAS, APC | LATS1 1025/4885ALDH1A1 3926/4885SLC22A12 4129/4885 |
| US-20210094919-A1 | KRAS MUTANT PROTEIN INHIBITORS | KRAS, NRAS, APC | LATS1 918/4885ALDH1A1 4345/4885SLC22A12 4251/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.